Precision Medicine Online6 小时
Servier Licenses Black Diamond Therapeutics' RAF-Targeted Solid Tumor Candidate
In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.